Adam Elsesser: Yes. So our philosophy has always been that we don’t want the commercial team to lead the selling. We want the products to be wanted, and then we have to have enough people to do the work and support those products. And we have always had what I consider the best commercial team, ever assembled, and we’ve been extraordinarily proud of our commercial team for many, many years. We just had so much to do last year between the launch of both Flash and Bolt at the same time. Our peripheral embolization business, which is again market leading technology, and on all these new customers that we talked about for a big chunk of last year. So we need more people, to do the work. Those people are now here. They’re on board.
We were able to hire some of the best folks, we could. So I think we have really today an optimized sized team. As this continues, could we — would we add to it? Sure. It’s not impossible, but it’s certainly not in our plans, anytime soon as we continue to go through this year. I think we got the team we need to drive this kind of growth we’re talking about and serve the patients and physicians that we need to serve this year.
Michael Matson: Okay. Got it. Thank you.
Adam Elsesser: Thank you.
Operator: [Operator Instructions]. Our next question comes from Shagun Singh from RBC Capital. Your line is now open.
Shagun Singh Chadha: Great. Thank you so much. So Adam, you’re targeting 16% to 20% growth here in ’24 versus your initial directional outlook of plus 20%. I was just wondering, is there a pathway for you to return to that plus 20% growth, and what could potentially be the drivers of it? Is it Flash 2.0? Is it the new product that you alluded to that we could see this year? And then really the question is how should we think about growth longer-term for Penumbra? Is there a plus 20% base case on the horizon? And then just as a follow-up, on Q2, just wondering if there’s any color you can provide. Prior to today’s call, consensus was looking at $3.02 for sales and $0.61 for EPS. Any color would be great? Thank you for taking the questions.
Adam Elsesser: Yes. Let me start on the first part. We’ve always looked sort of our philosophy around guidance is pretty straightforward. We look and take into account all the information we have at the time we give our guidance, and that has been our approach for some time. So I’m not going to sort of deviate from that and sort of guess what could happen here or there. Obviously, we are extremely happy with where the business is. We feel an awful lot of excitement and momentum around the products that we’ve added to this field, and we’re very proud of it. I think we’ll leave like the guessing of guidance for a future time beyond what we’ve said. That also being said, and this is not meant as a comment around guidance, it’s meant around a comment of the work we have ahead.
I also said in the prepared remarks that there’s 1.25 million people in the U.S. alone who have caught in their body, that we should consider doing something about and are potentially now more able to do something about than we’ve ever been in the past. And obviously, that lays out the work we have to do, and that will obviously impact our future thoughts around how the business will grow. But it’s premature to do that, and we’re going to focus on what we’re doing right now.
Jason Mills: Yes. And Shagun, to your second question, we reiterated today sort of the cadence of revenue growth we expect through the balance of the year. And we said the same thing on the initial guidance call in February, where the first part of the year, we expect it to be in the mid-teens range. Today, you obviously saw us report growth of a little over 15%. And we said that the second half of the year, we would see at the top end of the range or above. And part of that is the visibility we have in the international cadence. And, of course, we’ve talked a lot about our U.S. Thrombectomy business and the commercial team in the products Flash 2.0 among them there. So I think you have, we try to be comprehensive in my prepared remarks to give you the components of the business to set up your models, but happy to take any follow-ups if that’s not enough.
Shagun Singh Chadha: Thank you.
Adam Elsesser: Thank you.
Operator: There are no further questions at this time. Ms. Furlong, I turn the call back over to you.
Cecilia Furlong: Thank you, operator. On behalf of our management team, thank you all again for joining us today and for your interest in Penumbra. We look forward to updating you on our second quarter call.
Operator: This concludes today’s conference call. You may now disconnect.
